Collateral for a security interest recorded Apr 8, 2026 (Royal Bank of Canada).
Term ends Dec 13, 2026 · High confidence
20-year base term ended Oct 17, 2026
Held by Gen-Probe Incorporated
Filed Nov 13, 2017 as application 15/811,364 · Granted Apr 21, 2020
Base term plus 57 days of patent term adjustment (USPTO delay)
Today
2006
2026
Clock starts
Oct 17, 2006
Oct 17, 2006
Term ends
Dec 13, 2026
Dec 13, 2026
Granted
Apr 21, 2020
Apr 21, 2020
base term
patent term adjustment
fee events
Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
57
Days of term adjustment
Read from the USPTO patent term adjustment record, not recalculated here.
No effect
Terminal disclaimer
Resolved from the filed document, referencing US 9,845,509, to Dec 13, 2026. The term already ends on or before that date, so the cap shortened nothing.
1 of 1
Maintenance fees paid
One maintenance fee can end this term early, the one due 3.5 years from grant; the next one's grace period runs past the term end. This counts it if the record shows it paid.
4
Family applications on record here
Applications sharing this one's continuity chain whose file history this site holds. The family may have others.
This patent's term runs 57 days past its 20-year base term on prosecution delay. A terminal disclaimer is resolved from the filed document, and it ends no earlier than this term, so it shortens nothing. 1 of 1 maintenance fees is paid so far. Confidence: High. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Oct 17, 2006, when application 11/582,770, the earliest non-provisional in its chain, was filed (this one was filed Nov 13, 2017) | Oct 17, 2026 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | +57 days, USPTO patent term adjustment record | Dec 13, 2026 | High confidence |
| Terminal disclaimer cap | Disclaimer resolved from the filed document (refs US 9,845,509) | resolves to Dec 13, 2026, no earlier than this term, so no change | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 1 of 1 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | Dec 13, 2026 | High confidence |
This family
| Application 11/582,770 | Abandoned not computed | not computed |
| US 8,609,829 | In force Apr 2027 | Apr 2027 |
| US 9,845,509 | In force Oct 2027 | Oct 2027 |
| US 10,626,470 | this patent Dec 2026 | Dec 2026 |
The applications whose file history this site holds. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Oct 19, 2018 Reel 47272, frame 347 | Hologic, Inc.; Gen-Probe Incorporated; Cynosure, Inc.; Faxitron Bioptics, LLC | Bank of America, N.A., as Collateral Agent | Security Interest |
| Feb 3, 2020 Reel 51703, frame 363 | Bungo, Jennifer J.; Hogan, James J.; Pollner, Reinhold B.; Hudspeth, Marie K.; Kaplan, Shannon K.; Marlowe, Elizabeth M. | Gen-Probe Incorporated | Assignment of Assignor's Interest |
| Oct 15, 2020 Reel 54089, frame 804 | Hologic, Inc.; Faxitron Bioptics, LLC; Focal Therapeutics, Inc.; Gen-Probe Incorporated; Gen-Probe Prodesse, Inc. | Bank of America, N.A., as Collateral Agent | Security Interest |
| Apr 8, 2026 Reel 75462, frame 440 | Biotheranostics, Inc.; Gen-Probe Incorporated; Gen-Probe Prodesse, Inc.; Cytyc Corporation; Suros Surgical Systems, Inc.; Gynesonics, Inc.; Bolder Surgical, LLC; Faxitron Bioptics, LLC; Health Beacons, Inc.; Hologic, Inc. | Royal Bank of Canada, as Collateral Agent | Security Interest |
| Apr 8, 2026 Reel 75926, frame 339 | Biotheranostics, Inc.; Gen-Probe Incorporated; Gen-Probe Prodesse, Inc.; Cytyc Corporation; Suros Surgical Systems, Inc.; Gynesonics, Inc.; Bolder Surgical, LLC; Faxitron Bioptics, LLC; Health Beacons, Inc.; Hologic, Inc. | Citibank, N.A., as Collateral Agent | Security Interest |
| Apr 28, 2026 Reel 75504, frame 575 | Bank of America, N.A., as Collateral Agent | Hologic, Inc., on Its Own Behalf and as Successor-by-Merger to Focal Therapeutics, Inc.; Gen-Probe Incorporated; Faxitron Bioptics, LLC; Gen-Probe Prodesse, Inc. | Release of Security Interest Recorded at Reel/Frame 054089/0804 |
| Oct 16, 2026 Reel 76499, frame 106 | Bank of America, N.A., as Collateral Agent | Hologic, Inc.; Gen-Probe Incorporated; Cynosure, LLC, as Successor-by-Conversion to Cynosure, Inc.; Faxitron Bioptics, LLC | Release of Security Interest Recorded at Reel/Frame 047272/0347 |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
What's changing
Dec 2026
Term ends Dec 13, 2026. No further fees fall due before then
Note
The 57 days of patent term adjustment (USPTO delay) are read from the USPTO record, not recalculated by us
Terminal disclaimer
A terminal disclaimer resolved from the filed document, referencing US 9,845,509, ends no earlier than this term, so it caps nothing.
Citations
0
later US patents cite this one
That is below the median of utility patents granted in 2020 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.